Compared with expected rates, the age- and sex-adjusted standardized incidence ratio for all malignancies (excluding nonmelanoma skin cancer) among tofacitinib-treated patients was 1.17 (95% CI 0.96-1.41), according to Jeffrey R. Curtis, MD, of the University of Alabama at Birmingham, and colleagues.